九强生物：近日收到北京市药品监督管理局颁发的《医疗器械注册证》

Group 1 - The core point of the article is that Jiukang Bio has received a medical device registration certificate from the Beijing Drug Administration for products including "D-Dimer Calibration Products" [1] - Jiukang Bio's revenue composition for the year 2024 is projected to be 100% from the healthcare sector [1] - As of the report, Jiukang Bio has a market capitalization of 7.8 billion yuan [1] Group 2 - The article also mentions Yang Lingjiang's acquisition of a leading domestic winery, raising questions about the potential relisting of 1919 [1] - There is a sense of urgency expressed regarding the achievement of a significant financial target, indicating pressure on the company [1]